Furthermore, the study focused exclusively on anti-Sm, anti-Ro, and anti-RNP antibodies without accounting for other potentially relevant biomarkers or complement levels, which could provide additional insights into LN progression. This evidence concerns the gene CALR and lobular neoplasia.